Boston Life Sciences, Inc. Product Pipeline

(information and links below last updated: Winter 2005)

  © Boston Life Sciences. 2006. All rights reserved. Important Legal Notice


We proudly engaged our marketing firm through:
Great Agencies - Marketplace for SEO and Digital Marketing Companies
(888) 222-8311
Located in the Sunnyvale City Center
support@greatagencies.com

ALTROPANE®

123 I-Based imaging agent for the early diagnosis of Parkinson's Disease (PD).

POET-1 Phase III trial ended early to evaluate full data set.  Results expected in Q3 2006.

ALTROPANE®

123 I-Based imaging agent for the objective diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)

Phase II

Inosine

Nerve growth factors for the treatment of stroke and spinal cord injury.

Pre-Clinical

FLUORATEC™

Technetium (99Tc) based imaging agent for the diagnosis of PD and ADHD

Pre-Clinical

O-1369

Novel DAT Blocker for the treatment of Parkinson's Disease

Pre-Clinical